Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SR1-7
mRNA-1975 · 1 trial · 1 indication
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
A MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor were required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Arm | Type | Description |
|---|---|---|
| mRNA-1975: Dose 1 | EXPERIMENTAL | Participants will receive 3 intramuscular (IM) injections of the mRNA-1975 vaccine at Dose Level 1 on Days 1, 57, and 169. |
| mRNA-1975: Dose 2 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 2 on Days 1, 57, and 169. |
| mRNA-1975: Dose 3 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose Level 3 on Days 1, 57, and 169. |
| mRNA-1975: Dose 4 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 4 on Days 1, 57, and 169. |
| mRNA-1982: Dose 1 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 1 on Days 1, 57, and 169. |
| mRNA-1982: Dose 2 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 2 on Days 1, 57, and 169. |
| mRNA-1982: Dose 3 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose level 3 on Days 1, 57, and 169. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive 3 IM injections of vaccine-matching placebo on Days 1, 57, and 169. |
| Name | Type | Description |
|---|---|---|
| mRNA-1975 | BIOLOGICAL | Dispersion delivered IM |
| mRNA-1982 | BIOLOGICAL | Dispersion delivered IM |
| Placebo | BIOLOGICAL | Solution delivered IM |
Inclusion Criteria: * Body mass index of 18 to 39 kilograms/square meter (inclusive) at the Screening Visit. * Participants of nonchildbearing potential may be enrolled in the study. * For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstaine...
Top 20 of 30 competitors
mRNA-1975 is an investigational vaccine being developed for the prevention of Lyme Disease. It is an mRNA-based vaccine candidate from Moderna, Inc. (ticker: MRNA). It is not approved for use and remains in clinical development.
mRNA-1975 is being developed by Moderna, Inc., which trades under the ticker MRNA. Moderna is the sponsor of the clinical program evaluating this Lyme Disease vaccine candidate.
mRNA-1975 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational vaccine candidate and has not been approved by the FDA.
mRNA-1975 has been evaluated in the Phase 1 trial NCT05975099, titled "A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age." The trial enrolled 807 participants in the United States and is completed.
The Phase 1 trial NCT05975099 was a randomized, double-blind, placebo-controlled study. It enrolled 807 healthy volunteers aged 18 through 70 years and evaluated safety and immunogenicity against Lyme Disease. The trial was conducted in the United States and is now completed.